The 17p deletion, frequently accompanied by TP53 mutations, represents a poor prognostic factor in CLL, given TP53’s essential role in cell cycle regulation, DNA repair, and apoptosis, ultimately leading to shorter treatment-free intervals and diminished overall survival [6,7]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.